Wave Life Sciences Ltd Forecasted to Post Q1 2020 Earnings of ($1.15) Per Share (NASDAQ:WVE)

Share on StockTwits

Wave Life Sciences Ltd (NASDAQ:WVE) – Research analysts at Svb Leerink issued their Q1 2020 earnings estimates for Wave Life Sciences in a note issued to investors on Thursday, December 5th. Svb Leerink analyst M. Foroohar expects that the company will post earnings per share of ($1.15) for the quarter. Svb Leerink also issued estimates for Wave Life Sciences’ Q2 2020 earnings at ($1.14) EPS, Q3 2020 earnings at ($1.14) EPS, Q4 2020 earnings at ($1.04) EPS and FY2020 earnings at ($4.47) EPS.

Wave Life Sciences (NASDAQ:WVE) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($1.48) EPS for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.14). Wave Life Sciences had a negative return on equity of 128.21% and a negative net margin of 1,015.84%. The company had revenue of $2.93 million for the quarter, compared to analyst estimates of $6.30 million.

A number of other brokerages have also recently commented on WVE. ValuEngine raised Wave Life Sciences from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, October 29th. Mizuho initiated coverage on Wave Life Sciences in a report on Thursday, November 21st. They set a “buy” rating and a $65.00 price target for the company. BidaskClub upgraded Wave Life Sciences from a “buy” rating to a “strong-buy” rating in a report on Wednesday, December 4th. HC Wainwright set a $33.00 price target on Wave Life Sciences and gave the stock a “buy” rating in a report on Wednesday, October 9th. Finally, Zacks Investment Research downgraded Wave Life Sciences from a “buy” rating to a “hold” rating in a report on Saturday, October 19th. Three research analysts have rated the stock with a hold rating, four have given a buy rating and two have assigned a strong buy rating to the stock. Wave Life Sciences has an average rating of “Buy” and an average target price of $45.00.

Shares of Wave Life Sciences stock opened at $35.11 on Monday. The company has a quick ratio of 1.88, a current ratio of 1.88 and a debt-to-equity ratio of 0.26. Wave Life Sciences has a 12 month low of $17.59 and a 12 month high of $50.98. The business has a fifty day simple moving average of $28.73 and a 200 day simple moving average of $24.42. The stock has a market cap of $1.11 billion, a PE ratio of -6.94 and a beta of 0.91.

Several institutional investors and hedge funds have recently modified their holdings of the company. Janus Henderson Group PLC lifted its stake in Wave Life Sciences by 16.1% in the 2nd quarter. Janus Henderson Group PLC now owns 3,392,298 shares of the company’s stock worth $88,505,000 after acquiring an additional 470,402 shares in the last quarter. Athanor Capital LP bought a new position in shares of Wave Life Sciences during the 2nd quarter worth approximately $566,000. Swiss National Bank lifted its position in shares of Wave Life Sciences by 2.4% during the 2nd quarter. Swiss National Bank now owns 34,200 shares of the company’s stock worth $892,000 after buying an additional 800 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Wave Life Sciences by 8.7% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 115,769 shares of the company’s stock worth $3,021,000 after buying an additional 9,273 shares during the period. Finally, Virtus ETF Advisers LLC lifted its position in shares of Wave Life Sciences by 93.3% during the 2nd quarter. Virtus ETF Advisers LLC now owns 10,387 shares of the company’s stock worth $271,000 after buying an additional 5,014 shares during the period. Institutional investors own 90.00% of the company’s stock.

In other news, Director Gregory L. Verdine sold 30,039 shares of the firm’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $30.63, for a total value of $920,094.57. Following the completion of the sale, the director now directly owns 36,009 shares in the company, valued at approximately $1,102,955.67. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Chandra Vargeese sold 6,000 shares of the firm’s stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $32.34, for a total value of $194,040.00. Company insiders own 39.70% of the company’s stock.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Featured Article: FTSE 100 Index

Earnings History and Estimates for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Boenning Scattergood Research Analysts Increase Earnings Estimates for Unity Bancorp, Inc.
Boenning Scattergood Research Analysts Increase Earnings Estimates for Unity Bancorp, Inc.
AXA  PT Set at €29.00 by Goldman Sachs Group
AXA PT Set at €29.00 by Goldman Sachs Group
Wintrust Financial Corp  Expected to Post Q1 2020 Earnings of $1.34 Per Share
Wintrust Financial Corp Expected to Post Q1 2020 Earnings of $1.34 Per Share
Q4 2019 EPS Estimates for Ardmore Shipping Corp  Cut by Analyst
Q4 2019 EPS Estimates for Ardmore Shipping Corp Cut by Analyst
Q4 2019 EPS Estimates for Eagle Bulk Shipping Inc. Lowered by Analyst
Q4 2019 EPS Estimates for Eagle Bulk Shipping Inc. Lowered by Analyst
Q4 2019 Earnings Estimate for Focus Financial Partners Inc Issued By Oppenheimer
Q4 2019 Earnings Estimate for Focus Financial Partners Inc Issued By Oppenheimer


© 2006-2020 Ticker Report